Exclusive to FirstWord Pharma PLUS subscribers - register for our live presentation on Thursday (October 29) of findings from a survey of 120 oncologists evaluating how new clinical data will shape the treatment of triple-negative and adjuvant HR+/HER2- breast cancer.
Questions asked to breast cancer specialists from US, France, Germany and UK:
To help FirstWord Pharma PLUS subscribers better understand how recent developments will impact the use of these therapies we will be presenting findings from a survey of 120 oncologists at an exclusive FW Live: FirstImpact event next Thursday (October 29). Please click here to register if you are a FirstWord Pharma Plus user or here to find out how to become a FirstWord Pharma PLUS subscriber.
FirstImpact is the newest addition to our Insight, Analysis and Views content offering FirstWord Pharma PLUS subscribers access each year to up to a dozen live events where our analysts present analysis of breakthrough clinical data based on physician surveys. It changes the game in pharmaceutical market news, providing industry professionals with superior analyses of the most important and disruptive clinical catalysts from the unique vantage point of prescribers.
As always, FirstWord would very much like to receive your feedback and suggestions.
To read more Physician Views articles, click here.